SK6842000A3 - A mixture of inhibitors, a combined pharmaceutical composition comprising the same and use thereof - Google Patents

A mixture of inhibitors, a combined pharmaceutical composition comprising the same and use thereof Download PDF

Info

Publication number
SK6842000A3
SK6842000A3 SK684-2000A SK6842000A SK6842000A3 SK 6842000 A3 SK6842000 A3 SK 6842000A3 SK 6842000 A SK6842000 A SK 6842000A SK 6842000 A3 SK6842000 A3 SK 6842000A3
Authority
SK
Slovakia
Prior art keywords
compound
indinavir
pharmaceutically acceptable
acceptable salt
ester
Prior art date
Application number
SK684-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Joseph P Vacca
Jiunn H Lin
Kuang C Yeh
Jeffrey A Chodakewitz
Paul J Deutsch
William D Ju
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9807938.7A external-priority patent/GB9807938D0/en
Priority claimed from GBGB9819590.2A external-priority patent/GB9819590D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of SK6842000A3 publication Critical patent/SK6842000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK684-2000A 1997-11-13 1998-11-12 A mixture of inhibitors, a combined pharmaceutical composition comprising the same and use thereof SK6842000A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6542197P 1997-11-13 1997-11-13
GBGB9807938.7A GB9807938D0 (en) 1998-04-15 1998-04-15 Combination therapy for the treatment of AIDS
US9094098P 1998-06-26 1998-06-26
GBGB9819590.2A GB9819590D0 (en) 1998-09-08 1998-09-08 Combination therapy for the treatment of aids
PCT/US1998/024097 WO1999025352A1 (en) 1997-11-13 1998-11-12 Combination therapy for the treatment of aids

Publications (1)

Publication Number Publication Date
SK6842000A3 true SK6842000A3 (en) 2000-12-11

Family

ID=27451773

Family Applications (1)

Application Number Title Priority Date Filing Date
SK684-2000A SK6842000A3 (en) 1997-11-13 1998-11-12 A mixture of inhibitors, a combined pharmaceutical composition comprising the same and use thereof

Country Status (24)

Country Link
EP (1) EP1044000B1 (xx)
JP (1) JP2001522889A (xx)
KR (1) KR20010032055A (xx)
CN (1) CN1285747A (xx)
AR (1) AR013758A1 (xx)
AT (1) ATE218866T1 (xx)
AU (1) AU749795B2 (xx)
BG (1) BG104507A (xx)
BR (1) BR9814146A (xx)
CA (1) CA2309164A1 (xx)
CO (1) CO4970782A1 (xx)
DE (1) DE69806062T2 (xx)
EA (1) EA200000513A1 (xx)
ES (1) ES2177103T3 (xx)
HU (1) HUP0100365A3 (xx)
ID (1) ID24922A (xx)
IL (1) IL135994A0 (xx)
IS (1) IS5481A (xx)
NO (1) NO20002481L (xx)
PE (1) PE20000020A1 (xx)
PL (1) PL340430A1 (xx)
SK (1) SK6842000A3 (xx)
TR (1) TR200001938T2 (xx)
WO (1) WO1999025352A1 (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
AU2002355739A1 (en) 2001-07-30 2003-02-17 University Of Southern California Preparation and use of alpha-keto phosphonates
SI1583542T1 (sl) * 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
GB2400553A (en) * 2003-04-14 2004-10-20 Cipla Ltd Antiviral pharmaceutical combination of lamivudine, stavudine and efavirenz, or derivatives thereof
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046727C (zh) * 1993-12-15 1999-11-24 麦克公司 Hiv蛋白酶抑制剂

Also Published As

Publication number Publication date
NO20002481L (no) 2000-07-12
AU1522599A (en) 1999-06-07
IS5481A (is) 2000-05-09
CA2309164A1 (en) 1999-05-27
JP2001522889A (ja) 2001-11-20
ID24922A (id) 2000-08-31
CO4970782A1 (es) 2000-11-07
BR9814146A (pt) 2000-10-03
HUP0100365A3 (en) 2002-06-28
IL135994A0 (en) 2001-05-20
AR013758A1 (es) 2001-01-10
ATE218866T1 (de) 2002-06-15
TR200001938T2 (tr) 2001-07-23
HUP0100365A2 (hu) 2002-05-29
PL340430A1 (en) 2001-02-12
EA200000513A1 (ru) 2000-10-30
BG104507A (bg) 2001-03-30
ES2177103T3 (es) 2002-12-01
WO1999025352A1 (en) 1999-05-27
CN1285747A (zh) 2001-02-28
KR20010032055A (ko) 2001-04-16
AU749795B2 (en) 2002-07-04
EP1044000B1 (en) 2002-06-12
DE69806062D1 (de) 2002-07-18
PE20000020A1 (es) 2000-01-27
EP1044000A1 (en) 2000-10-18
DE69806062T2 (de) 2003-03-20
NO20002481D0 (no) 2000-05-12

Similar Documents

Publication Publication Date Title
DE69534549T2 (de) Kombination von retroviralen Proteasehemmern
KR101524165B1 (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
AU762125B2 (en) Use of (N)-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
WO1995010281A1 (en) Combination therapy for hiv infection
US6180634B1 (en) Combination therapy for the treatment of AIDS
US20020115665A1 (en) Methods of and compounds for inhibiting calpains
EP1063888A1 (en) Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
SK6842000A3 (en) A mixture of inhibitors, a combined pharmaceutical composition comprising the same and use thereof
EP0806957B1 (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir adn the reverse transcriptase inhibitor 3tc together with azt.
CN108440446B (zh) 含有肟基片段的苯并噻嗪-4-酮类化合物及其制备方法
WO1996000068A2 (en) Combination therapy for hiv infection
CA2197207C (en) Hiv protease inhibitor combination
CZ20001752A3 (cs) Farmaceutické prostředky obsahující kombinaci pro léčbu AIDS
US20050049242A1 (en) Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
WO1999011617A1 (fr) Nouveaux derives de naphtamide et sels de ces derives
SK163299A3 (en) Sulfate salt of n-(2(r)-hydroxy-1(s)-indanyl)-2(r)-phenylmethyl- 4-(s)-hydroxy-5-(1-(4-(2-benzo[b]furanylmethyl)-2(s)-n'-(terc- butylcarboxamide)piperazinyl))pentanamide in a crystalline form, pharmaceutical composition containing the same and use thereof
RU2194506C2 (ru) Сочетание ингибиторов вич-протеазы
NZ732033B2 (en) Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia
MXPA99011018A (en) Sulfate salt of an hiv protease inhibitor having an improved oral absorption and bioavailability
CZ425199A3 (cs) Sulfát inhibitoru HIV proteázy
JPH10182596A (ja) 脂質代謝改善剤